Compass Pathways (CMPS)

by | Jan 7, 2021 | Daily Trade Alert

One of the most interesting investing stories is psychedelics.

With US FDA support, clinical research studies, and legalization in Oregon, related stocks are starting to see some momentum. So far, research has offered proof that psychedelics like psilocybin can be useful in the treatment of depression, anxiety, obsessive-compulsive disorder, addiction, and PTSD.

That being the case, one of the stocks getting caught up in the boom is Compass Pathways (CMPS), which is researching the impact of psilocybin and mental health. If all goes well, psychedelics could see the same momentum that drove cannabis stocks to higher highs.

Related Content